With positive data, Madrigal Pharma joins lucrative race for drug to treat fatty liver disease

Updated with additional information.

Nine months of treatment with an experimental pill from Madrigal Pharmaceuticals resulted in the significant reversal of the fatty liver disease known as NASH, according to updated data from a placebo-controlled clinical trial released Thursday.

A significantly greater number of patients taking the Madrigal drug also saw NASH liver symptoms resolve completely. There was a more modest reduction in the most troublesome tissue-scarring process known as fibrosis. The Madrigal drug is called MGL-3196.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In